Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Lentiviral Vector Market Expected to Be in 2029?

In the past few years, the lentiviral vector market has seen substantial growth. The market is projected to increase from $14.37 billion in 2024 to $16.48 billion in 2025, with a compound annual growth rate (CAGR) of 14.7%. The growth during the historic period is a reflection of the prevalence of genetic disorders, demand for gene delivery, expansion of biotech and pharma industries, investment in clinical trials, and regulatory approvals.

In the coming years, the lentiviral vector market is projected to experience swift expansion, expected to reach a market size of “$27.71 billion in 2029, boasting a Compound Annual Growth Rate (CAGR) of 13.9%. The predicted growth during this period is due to factors like the rise in personalized medicine, advancements in gene editing, increasing demand for therapy for rare diseases, adoption of lentiviral vector, financing of genomic medicine, and an emphasis on manufacturing scalability. The forecast period is set to witness significant trends including an upsurge in research and development, integration into CAR-T cell therapy, creation of next-generation vectors, implementation in vaccine development, and evolution of production technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14742&type=smp

What Are The Contributors To Demand In The Lentiviral Vector Market?

A rise in chronic disease occurrences, which are long-standing health issues that slowly progress over time and often last a lifetime, are anticipated to boost the lentiviral vectors market. The increasing instances of chronic diseases can be attributed to factors such as aging populations, unhealthy lifestyle patterns, urban development, and environmental influences. Lentiviral vectors can efficiently and adaptively contribute to the development of chronic disease treatments and vaccines, hence, addressing unfulfilled clinical demands and enhancing patient health outcomes. As per information in September 2024, by the British Heart Foundation, a cardiovascular investigation charity based in the UK, approximately 7.6 million individuals suffer from cardiac and circulatory diseases in the UK, with about 4 million men and 3.6 million women having these illnesses. These conditions cause nearly 27% of all demises in the UK, resulting in about 170,000 deaths per annum, approximating to 480 fatalities daily, implying one death every three minutes. Thus, the rising occurrence of chronic diseases is propelling the growth of the lentiviral vectors market.

The lentiviral vector market covered in this report is segmented –

1) By Product Type: Kits, Reagents And Consumables

2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications

3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes

Subsegments:

1) By Kits: Lentiviral Transduction Kits, Lentiviral Packaging Kits, Lentiviral Vector Production Kits

2) By Reagents and Consumables: Lentiviral Packaging Reagents, Lentiviral Vector Concentration Reagents, Transfection Reagents for Lentiviral Vectors

How Are Key Trends Driving Expansion In The Lentiviral Vector Industry?

Key players in the lentiviral vectors market, such as LentiSure, are investing in the development of LV vector production platforms to improve the efficiency and effectiveness of lentivirus vector production for use in cell-based immuno-oncology therapies. LentiSure, a LV vector production platform, is engineered to maximize productivity and reliability in vector creation. It is extensively utilized in manufacturing lentiviral vectors for cell-based immuno-oncology therapies. For example, in May 2023, Yposkesi sk pharmteco, a viral vector production company based in France, introduced LentiSure, an innovative platform designed to optimize the production of lentiviral (LV) vectors. It aims to enhance lentivirus production’s resilience and efficiency. The platform meets the increasing need for robust and economically scalable viral-vector manufacturing technologies required in cell and gene therapies. It provides consistent product quality with an average titer at cell culture harvest of 10e7 IG/mL bioreactor volume, guaranteeing superior productivity and successful outcomes for cell therapy developers.

Who Are The Top-Ranked Companies In The Lentiviral Vector Market Today?

Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi

https://www.thebusinessresearchcompany.com/report/lentiviral-vector-global-market-report

How Is Lentiviral Vector Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the lentiviral vector market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=14742&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.